Education
About Us
Working with TipRanks
Follow Us
NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
Total Valuation
NewAmsterdam Pharma Company has a market cap or net worth of $4.05B. The enterprise value is $3.54B.
Market Cap$4.05B
Enterprise Value$3.54B
Share Statistics
NewAmsterdam Pharma Company has 113,390,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding113,390,800
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
NewAmsterdam Pharma Company’s return on equity (ROE) is -0.30 and return on invested capital (ROIC) is -33.01%.
Return on Equity (ROE)-0.30
Return on Assets (ROA)-0.26
Return on Invested Capital (ROIC)-33.01%
Return on Capital Employed (ROCE)-0.33
Revenue Per Employee330.93K
Profits Per Employee0.00
Employee Count68
Asset Turnover0.03
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of NewAmsterdam Pharma Company is ―. NewAmsterdam Pharma Company’s PEG ratio is 0.62.
PE Ratio―
PS Ratio178.34
PB Ratio5.87
Price to Fair Value5.87
Price to FCF-27.11
Price to Operating Cash Flow-27.54
PEG Ratio0.62
Income Statement
In the last 12 months, NewAmsterdam Pharma Company had revenue of 22.50M and earned -203.82M in profits. Earnings per share was -1.75.
Revenue22.50M
Gross Profit22.44M
Operating Income-225.68M
Pretax Income-203.82M
Net Income-203.82M
EBITDA-242.32M
Earnings Per Share (EPS)-1.75
Cash Flow
In the last 12 months, operating cash flow was -147.78M and capital expenditures -246.00K, giving a free cash flow of -148.03M billion.
Operating Cash Flow-147.78M
Free Cash Flow-148.03M
Free Cash Flow per Share-1.31
Dividends & Yields
NewAmsterdam Pharma Company pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.20
52-Week Price Change102.97%
50-Day Moving Average34.10
200-Day Moving Average28.61
Relative Strength Index (RSI)57.48
Average Volume (3m)622.63K
Important Dates
NewAmsterdam Pharma Company upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateFeb 18, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
NewAmsterdam Pharma Company as a current ratio of 7.88, with Debt / Equity ratio of 0.03%
Current Ratio7.88
Quick Ratio7.88
Debt to Market Cap<0.01
Net Debt to EBITDA2.02
Interest Coverage Ratio0.00
Taxes
In the past 12 months, NewAmsterdam Pharma Company has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
NewAmsterdam Pharma Company EV to EBITDA ratio is -14.54, with an EV/FCF ratio of -23.80.
EV to Sales156.57
EV to EBITDA-14.54
EV to Free Cash Flow-23.80
EV to Operating Cash Flow-23.84
Balance Sheet
NewAmsterdam Pharma Company has $636.24M in cash and marketable securities with $202.00K in debt, giving a net cash position of $636.04M billion.
Cash & Marketable Securities$636.24M
Total Debt$202.00K
Net Cash$636.04M
Net Cash Per Share$5.61
Tangible Book Value Per Share$5.97
Margins
Gross margin is 99.74%, with operating margin of -1002.90%, and net profit margin of -905.74%.
Gross Margin99.74%
Operating Margin-1002.90%
Pretax Margin-905.74%
Net Profit Margin-905.74%
EBITDA Margin-1076.86%
EBIT Margin-1077.83%
Analyst Forecast
The average price target for NewAmsterdam Pharma Company is $47.56, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$47.56
Price Target Upside33.67% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast―
EPS Growth Forecast―